Alterations of B lymphocyte Fc gamma R II expression and ligand binding capacity induced by various activators

Area of Science:

• Immunology
• Cell Biology
• Molecular Signaling

Background:

• B lymphocytes play a crucial role in adaptive immunity.
• Fc gamma RII (FcγRII) on B cells mediates interactions with IgG antibodies and immune complexes.
• The regulation of FcγRII expression and function is critical for B cell activation and immune responses.

Purpose of the Study:

• To investigate the effects of different B lymphocyte activators on Fc gamma RII binding capacity.
• To elucidate the mechanisms underlying anti-mu-induced alterations in FcγRII ligand binding.
• To compare the impact of anti-mu antibodies with other B cell activators like LPS.

Main Methods:

• Culturing murine B lymphocytes with F(ab')2 anti-mouse mu or delta antibodies.
• Assessing the binding capacity of antigen-IgG antibody complexes using flow microfluorometry.
• Evaluating Fc gamma RII expression with monoclonal anti-Fc gamma RII antibodies.
• Stimulating cells with PMA and calcium ionophore to investigate signaling pathways.

Main Results:

• Culture with anti-mu antibodies significantly reduced B lymphocyte binding of immune complexes (85%).
• This reduction was concentration, time, and temperature dependent, and reversible.
• Fc gamma RII expression remained unaffected, suggesting altered ligand binding rather than receptor downregulation.
• Activation of protein kinase C (PKC) and elevated intracellular calcium ([Ca2+]i) mimicked the anti-mu effect.
• Lipopolysaccharide (LPS) treatment resulted in a threefold increase in Fc gamma RII expression.

Conclusions:

• Anti-mu antibody stimulation alters Fc gamma RII ligand binding capacity, potentially via PKC and calcium signaling pathways.
• Different B lymphocyte activators exert distinct effects on Fc gamma RII, influencing downstream regulatory signals.
• Understanding these differential effects is key to comprehending B cell-mediated immune regulation.